Study of Apixaban for the Prevention of Thrombosis-related Events Following Knee Replacement Surgery

Overview[ - collapse ][ - ]

Purpose The purpose of this study is to learn if apixaban can prevent blood clots in the leg (deep vein Thrombosis [DVT]) and lung (pulmonary embolism [PE]) that sometimes occur after knee replacement surgery and to learn how apixaban compares to enoxaparin (Lovenox®) for preventing these clots. The safety of apixaban will also be studied.
ConditionDeep Vein Thrombosis
Pulmonary Embolism
InterventionDrug: Enoxaparin + Placebo
Drug: Apixaban + Placebo
PhasePhase 3
SponsorBristol-Myers Squibb
Responsible PartyBristol-Myers Squibb
ClinicalTrials.gov IdentifierNCT00371683
First ReceivedAugust 30, 2006
Last UpdatedSeptember 10, 2010
Last verifiedAugust 2009

Tracking Information[ + expand ][ + ]

First Received DateAugust 30, 2006
Last Updated DateSeptember 10, 2010
Start DateNovember 2006
Estimated Primary Completion DateMay 2008
Current Primary Outcome MeasuresA combination of asymptomatic and symptomatic DVT, non-fatal PE and all-cause death [Time Frame: after 12 days of treatment] [Designated as safety issue: No]
Current Secondary Outcome Measures
  • The following combined endpoints: [Time Frame: after 12 days of treatment]
  • Proximal DVT, non-fatal PE, and all-cause death [Time Frame: after 12 days of treatment] [Designated as safety issue: No]
  • Symptomatic DVT, non-fatal and fatal PE [Time Frame: after 12 days of treatment] [Designated as safety issue: No]
  • Major and non-major bleeding events [Time Frame: after 12 days of treatment] [Designated as safety issue: Yes]
  • Myocardial infarction and stroke [Time Frame: after 12 days of treatment] [Designated as safety issue: Yes]

Descriptive Information[ + expand ][ + ]

Brief TitleStudy of Apixaban for the Prevention of Thrombosis-related Events Following Knee Replacement Surgery
Official TitleA Phase 3 Randomized, Double-Blind Active-Controlled (Enoxaparin), Parallel-Group, Multi-Center Study to Evaluate the Safety and Efficacy of Oral Apixaban in Subjects Undergoing Elective Total Knee Replacement Surgery
Brief Summary
The purpose of this study is to learn if apixaban can prevent blood clots in the leg (deep
vein Thrombosis [DVT]) and lung (pulmonary embolism [PE]) that sometimes occur after knee
replacement surgery and to learn how apixaban compares to enoxaparin (Lovenox®) for
preventing these clots. The safety of apixaban will also be studied.
Detailed DescriptionNot Provided
Study TypeInterventional
Study PhasePhase 3
Study DesignAllocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention
Condition
  • Deep Vein Thrombosis
  • Pulmonary Embolism
InterventionDrug: Enoxaparin + Placebo
Syringes + tablets, Subcutaneous + Oral, 30mg, twice daily, 12 day treatment period
Other Names:
Lovenox®Drug: Apixaban + Placebo
Tablet + Syringes, Oral + subcutaneous, 2.5 mg, twice daily, 12 day treatment period
Study Arm (s)
  • Active Comparator: A1
    + placebo
  • Experimental: A2
    + placebo

Recruitment Information[ + expand ][ + ]

Recruitment StatusCompleted
Estimated Enrollment3202
Estimated Completion DateMay 2008
Estimated Primary Completion DateMay 2008
Eligibility Criteria
Inclusion Criteria:

- Men and non-pregnant, non-breastfeeding women

- 18 years or older

- Scheduled for knee replacement surgery

Exclusion Criteria:

- hereditary or acquired bleeding disorders

- clotting disorders

- bleeding or high risk for bleeding

- drugs that affect bleeding or coagulation
GenderBoth
Ages18 Years
Accepts Healthy VolunteersNo
ContactsNot Provided
Location CountriesUnited States, Argentina, Australia, Brazil, Canada, Denmark, Hungary, Israel, Mexico, Poland, Russian Federation, Sweden, Turkey

Administrative Information[ + expand ][ + ]

NCT Number NCT00371683
Other Study ID NumbersCV185-034
Has Data Monitoring CommitteeYes
Information Provided ByBristol-Myers Squibb
Study SponsorBristol-Myers Squibb
CollaboratorsNot Provided
Investigators Study Director: Bristol-Myers Squibb Bristol-Myers Squibb
Verification DateAugust 2009

Locations[ + expand ][ + ]

Capstone Clinical Trials, Inc
Birmingham, Alabama, United States, 35205
Capstone Clinical Trials, Inc
Birmingham, Alabama, United States, 35209
West Alabama Research, Inc.
Tuscaloosa, Alabama, United States, 35406
Martin Bowen Hefley Orthopedics
Little Rock, Arkansas, United States, 72205
Colorado Orthopedic Consultants, Pc
Aurora, Colorado, United States, 80012
Colorado Joint Replacement
Denver, Colorado, United States, 80210
Jdpmedical Research
Denver, Colorado, United States, 80230
Orhtopaedic Physicians Of Colorado, P.C.
Englewood, Colorado, United States, 80113
Orthopedics Assocs Of Hartford
Hartford, Connecticut, United States, 06106
Anthony S. Unger, Md
Washington, District of Columbia, United States, 20006
Bay Pines Va Medical Center
Bay Pines, Florida, United States, 33744
Pab Clinical Research
Brandon, Florida, United States, 33511
Jacksonville Center For Clinical Research
Jacksonville, Florida, United States, 32216
Mark W. Hollmann, Md
Orange City, Florida, United States, 32763
Jewett Orthopaedic Clinic
Winter Park, Florida, United States, 32789
Atlanta Knee And Sports Medicine
Decatur, Georgia, United States, 30033
Intermountain Orthopaedics
Boise, Idaho, United States, 83702
Americana Orthopedics
Boise, Idaho, United States, 83702
Bluegrass Orthopaedics/Bmr
Lexington, Kentucky, United States, 40509
Charleston Orthopaedic Assocs.
Charleston, South Carolina, United States, 29414
Bone & Joint Clinic Of Houston
Houston, Texas, United States, 77030
Kelsey Seybold Clinic
Houston, Texas, United States, 77025
Gill Orthopedic Center
Lubbock, Texas, United States, 79410
Robert R. King, Md
Lubbock, Texas, United States, 79410
Unlimited Research
San Antonio, Texas, United States, 78217
Local Institution
Capital Federal, Buenos Aires, Argentina, 1012
Local Institution
Capital Federal, Buenos Aires, Argentina, 1426
Local Institution
Buenos Aires, Argentina, 7540
Local Institution
Buenos Aires, Argentina, 1280
Local Institution
Buenos Aires, Argentina, C1181
Local Institution
Buenos Aires, Argentina, 1425
Local Institution
Cordoba, Argentina, 5000
Local Institution
Garran, Australian Capital Territory, Australia, 2605
Local Institution
Camperdown, New South Wales, Australia, NSW 2050
Local Institution
Caringbah, New South Wales, Australia, 2229
Local Institution
Lismore, New South Wales, Australia, 2480
Local Institution
Gold Coast, Queensland, Australia, 4215
Local Institution
Adelaide, South Australia, Australia, 5011
Local Institution
Bedford Park, South Australia, Australia, 5042
Local Institution
Box Hill, Victoria, Australia, 3128
Local Institution
Windsor, Victoria, Australia, 3181
Local Institution
Perth, Western Australia, Australia, 6001
Local Institution
Curitiba, Parana, Brazil, 80060
Local Institution
Porto Alegre, Rio Grande Do Sul, Brazil, 90035
Local Institution
Porto Alegre, Rs, Rio Grande Do Sul, Brazil, 90020
Local Institution
Campinas, Sao Paulo, Brazil, 13083
Local Institution
S�o Paulo, Sao Paulo, Brazil, 05403
Local Institution
Edmonton, Alberta, Canada, T6G 2R7
Local Institution
Ajax, Ontario, Canada, L1S 2J5
Local Institution
Burlington, Ontario, Canada, L7R 4B7
Local Institution
Cambridge, Ontario, Canada, N1R 7L7
Local Institution
Chatham, Ontario, Canada, N7L 4T1
Local Institution
Dartmouth, Ontario, Canada, B2Y 2N6
Local Institution
Guelph, Ontario, Canada, N1E 6L9
Local Institution
Lindsay, Ontario, Canada, K9V 4M8
Local Institution
Newmarket, Ontario, Canada, L3Y 5G8
Local Institution
Niagara Falls, Ontario, Canada, L2E 6X2
Local Institution
Sarnia, Ontario, Canada, N7T 6H3
Local Institution
Scarborough, Ontario, Canada, M1S 4T7
Local Institution
Scarborough, Ontario, Canada, M3C 1W3
Local Institution
St. Catharines, Ontario, Canada, L2R 7P3
Local Institution
Stratford, Ontario, Canada, N5A 2N4
Local Institution
Waterloo, Ontario, Canada, N2J 1C4
Local Institution
Windsor, Ontario, Canada, N8W 1E6
Local Institution
Charlottetown, Prince Edward Island, Canada, C1A 1L2
Local Institution
Montreal, Quebec, Canada, H4J 1C5
Local Institution
Quebec, Canada, G1L 3L5
Local Institution
Horsholm, Denmark, 2970
Local Institution
Kopenhamn S, Denmark, 2300
Local Institution
Kecskemet, Hungary, 6000
Local Institution
Szekesfehervar, Hungary, 8000
Local Institution
Szolnok, Hungary, 5008
Local Institution
Afula, Israel, 18101
Local Institution
Beer-Sheva, Israel, 84101
Local Institution
Haifa, Israel, 31096
Local Institution
Holon, Israel, 58100
Local Institution
Kfar-Saba, Israel, 44281
Local Institution
Petach-Tikva, Israel, 49100
Local Institution
Rehovot, Israel, 76100
Local Institution
Zerifin, Israel, 70300
Local Institution
Tijuana, Baja California, Mexico, 22010
Local Institution
Df, Distrito Federal, Mexico, 07760
Local Institution
Df, Distrito Federal, Mexico, 05300
Local Institution
Df, Distrito Federal, Mexico, 01030
Local Institution
Guadalajara, Jalisco, Mexico, 44280
Local Institution
Monterrey, Nuevo Leon, Mexico, 64000
Local Institution
Monterrey, Nuevo Leon, Mexico, 64460
Local Institution
Cd Madero, Tamaulipas, Mexico, 89240
Local Institution
Jalapa, Veracruz, Mexico, 91020
Local Institution
Merida, Yucatan, Mexico, 97133
Local Institution
Merida, Yucatan, Mexico, 97070
Local Institution
Chihuahua, Mexico, 31000
Local Institution
Bialystok, Poland, 15276
Local Institution
Krakow, Poland, 31-826
Local Institution
Lodz, Poland, 91002
Local Institution
Lublin, Poland, 20954
Local Institution
Szczecin, Poland, 71252
Local Institution
Warszawa, Poland, 02005
Local Institution
Warszawa, Poland, 00909
Local Institution
Moscow, Russian Federation, 117333
Local Institution
Samara, Russian Federation, 443095
Local Institution
St. Petersburg, Russian Federation, 195257
Local Institution
Goteborg, Sweden, 416 85
Local Institution
Adana, Turkey, 01330
Local Institution
Bursa, Turkey, 16059
Local Institution
Mersin, Turkey, 33163
Local Institution
Trabzon, Turkey, 61030